Having trouble accessing articles? Reset your cache.

Pneumagen: out-competing viral sugar binding to prevent infection

Pneumagen targeting infections, cancer by co-opting and enhancing microbial carbohydrate binders

With its platform of carbohydrate-binding proteins, Pneumagen is co-opting a pathogenic tool for interacting with host cells to block infections and adapting the technology for use against cancer.

Both viruses and bacteria can interact with human cells via proteins that recognize sugar residues, including sialic acid, on proteoglycans.

However, the overwhelming majority of industry programs targeting the interaction have focused on viral infections, and most use small molecules to inhibit viral glycosidases, which upon mutation could render the virus drug-resistant.

Scotland-based Pneumagen Ltd., which emerged from stealth in

Read the full 850 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE